Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Health Behaviour Change

- PMLiVE

AstraZeneca’s Imfinzi regimen granted FDA approval to treat endometrial cancer

Mismatch repair-deficient disease accounts for up to 30% of endometrial cancer cases

- PMLiVE

Amgen’s Blincyto approved by FDA for new acute lymphoblastic leukaemia indication

More than 6,500 new cases of the blood cancer were diagnosed in the US last year

- PMLiVE

Janssen/Pharmacyclics’ ibrutinib shows continued survival benefit in chronic lymphocytic leukaemia

The slow-growing blood cancer affects approximately 4.92 per 100,000 people every year in Europe

- PMLiVE

Pfizer shares positive overall survival results for Elrexfio in multiple myeloma

The blood cancer is responsible for more than 187,000 new cases worldwide every year

- PMLiVE

Celltrion’s RoActemra biosimilar shows promise in phase 3 rheumatoid arthritis study

The chronic inflammatory disease affects approximately 1% of the population worldwide

- PMLiVE

Maximising the impact of creativity in healthcare

Embracing challenge and disruption to energise creative campaigns

- PMLiVE

AbbVie gains rights to FutureGen’s inflammatory bowel disease candidate in deal worth $1.7bn

The agreement gives AbbVie exclusive global rights to the TL1A-targeting monoclonal antibody

- PMLiVE

Bristol Myers Squibb’s Augtyro granted expanded FDA approval for solid tumours

The drug was approved by the US regulator last year to treat ROS1-positive NSCLC

- PMLiVE

Roche’s spinal muscular atrophy treatment Evrysdi shows continued benefit in children

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Pfizer/Flagship’s drug discovery partnership to focus on obesity treatments

The agreement with Profound Therapeutics is the first to be initiated under the partnership

Can Cinderella save us?

KCL research could speed up discovery of new antibiotics in fight against AMR

According to WHO, AMR is designated as one of the top ten global public health threats facing humanity

- PMLiVE

Innovation in oncology

Iona Everson from PMGroup spoke to Jack Harris, Vice President of Oncology at GSK, about his career path and his drive to improve patient care

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links